bendamustine + prednisolone

**Bendamustine + prednisolone** is a combination of two drugs: the alkylating agent bendamustine and the synthetic corticosteroid prednisolone. Bendamustine acts as a bifunctional alkylating agent that induces DNA cross-linking and subsequent cell death, exhibiting both alkylator and antimetabolite properties. Its unique structure with a benzimidazole ring may contribute to potent and distinct effects on DNA repair and apoptosis, with activity against both dividing and quiescent cells. Prednisolone is a glucocorticoid receptor agonist that leads to immunosuppression and reduction of inflammation, and can induce apoptosis in sensitive cancer cell lines. This combination is used primarily as first-line or salvage therapy for multiple myeloma, particularly for patients ineligible for regimens containing thalidomide or bortezomib, as well as various lymphoproliferative disorders. Clinical studies have shown that bendamustine + prednisolone offers similar or superior efficacy to standard regimens such as melphalan + prednisolone, but with a differentiated toxicity profile[1][6][2][4].